NAT10 Knockdown Improves Cisplatin Sensitivity in Non‐Small Cell Lung Cancer by Inhibiting the TRIM44/PI3K/AKT Pathway

• Published in: Thoracic cancer Vol. 16; no. 9; pp. e70079 - n/a
• Main Authors: Sun, Qi, Yang, Xiansong, Wang, Ye, Yang, Kejia, Weng, Yuan
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.05.2025; John Wiley & Sons, Inc; Wiley
• Subjects: Animals; Apoptosis; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - metabolism; Carcinoma, Non-Small-Cell Lung - pathology; Cell Proliferation; Cells; Cisplatin - pharmacology; Cisplatin - therapeutic use; DDP; Drug Resistance, Neoplasm; Enzymes; Female; Flow cytometry; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Kinases; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Lung Neoplasms - pathology; Male; Membranes; Mice; Mice, Nude; NAT10; non‐small cell lung cancer; Original; Phosphatidylinositol 3-Kinases - metabolism; PI3K/AKT pathway; Proteins; Proto-Oncogene Proteins c-akt - metabolism; Reagents; Signal Transduction; TRIM44; Tripartite Motif Proteins - genetics; Tripartite Motif Proteins - metabolism; Xenograft Model Antitumor Assays; Beijing China; United States > US; China; Shanghai China; DDP; NAT10; TRIM44; non‐small cell lung cancer; PI3K/AKT pathway

ABSTRACT Background Non‐small cell lung cancer (NSCLC) is a leading cause of cancer‐related deaths worldwide, and cisplatin (DDP) resistance remains a significant challenge in NSCLC treatment. Methods Quantitative reverse transcription polymerase chain reaction (qRT‐PCR) was used to analyze NAT10 an...